Data on AstraZeneca vaccine insufficient for Swiss approval
Last week Swissmedic received a large package of data from the pharmaceutical company, which it is now reviewing.
Copyright 2021 The Associated Press. All Rights Reserved
This content was published on
2 minutes
Keystone-SDA/gw
Español
es
Los datos de AstraZeneca son insuficientes para aprobación en Suiza
The medicines regulator Swissmedic says it has not yet received enough robust data from clinical trials to give the green light to the Covid-19 vaccine developed by the Swedish-British company.
While the supervisory authority saw conclusive results from studies involving many participants to approve two other coronavirus vaccines, the same could not be said for the Oxford-AstraZeneca shot, Swissmedic director Raimund Bruhin told the CH Media group of newspapers on Thursday.
But this did not mean that he believes the vaccine is a poor one.
“We are only saying that the company has not yet been able to prove to us that it is a good vaccine,” said Bruhin.
The approvals process, he added, was about hard data and facts. Last week Swissmedic received a large package of data from the pharmaceutical company, which it is now reviewing, and remains in regular contact with the makers of the vaccine.
Other countries, such as the United Kingdom, have been administering the AstraZeneca vaccine for over three months – although several nations have halted vaccinations in recent days over isolated cases of blood-clotting. The European Medicines Agency has said the benefits of the Oxford-AstraZeneca jab greatly outweigh the risks and on Thursday will issue a report on its investigation into cases of blood clots.
Switzerland has ordered more than 35 million doses of Covid-19 vaccines from five manufacturers. To date Swissmedic has approved shots developed by Pfizer/BioNTech and Moderna. Roughly 4% of the population has been vaccinated so far, but delays in approval and delivery have slowed the roll-out process.
Popular Stories
More
Swiss Abroad
The citizenship obstacle course facing spouses of Swiss Abroad
Top Swiss firms close to reaching gender quota in boards
This content was published on
The proportion of women on the boards of directors of the fifty largest listed companies in Switzerland currently stands at 28%.
Swiss committee wants to end government resignations during legislative term
This content was published on
Members of the Federal Council should no longer be able to leave office before the end of their term, according to a House of Representatives committee.
Swiss government seat: Ritter and Pfister nominated to succeed Amherd
This content was published on
Markus Ritter from St Gallen and Martin Pfister from Zug were officially nominated by the Centre Party on Friday to succeed Defence Minister Viola Amherd.
Top Swiss court rejects Russian request for administrative tax assistance
This content was published on
There is currently no reason to transmit banking information to the Russian Federation, the Swiss Federal Court has ruled.
After strike by radiologists, doctors demonstrate in Bern
This content was published on
Following a strike by radiology technicians in Fribourg, doctors, vets, dentists and chiropractors expressed their frustration on Friday outside parliament in the Swiss capital.
Eurovision and bleak world situation are top themes at Basel carnival
This content was published on
The Eurovision Song Contest and the gloomy global situation are among the main themes of Basel Fasnacht (carnival) this year.
Prices of Swiss investment properties continue to rise despite stagnating rents
This content was published on
Although rents in Switzerland stagnated or fell in the final quarter of last year, prices for investment properties continued to rise. Both apartment buildings and office properties have become more expensive.
Probe into wrong Swiss pension figures clears federal office
This content was published on
Employees of the Swiss Federal Social Insurance Office (FSIO) did not breach their duty of care when calculating pension prospects, an investigation has concluded.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Switzerland could sell or give away AstraZeneca doses if regulator dithers
This content was published on
A lack of green light from medicines regulator Swissmedic could see 5.3 million doses ordered by Switzerland sent elsewhere.
This content was published on
Media reports indicate that vaccinating everyone who wants to by summer relies on meeting ambitious vaccine delivery targets in spring.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.